西格莱克
免疫系统
免疫检查点
肿瘤微环境
封锁
生物
癌症研究
癌症
免疫疗法
免疫学
抗体
肿瘤进展
受体
遗传学
作者
Michal A. Stanczak,Natália Rodrigues Mantuano,Nicole Kirchhammer,David E. Sanin,Francis Jacob,Ricardo Coelho,Arun Everest‐Dass,Jinyu Wang,Marcel P. Trefny,Gianni Monaco,Anne Bärenwaldt,Melissa Anne Gray,Adam Petrone,Abhishek S. Kashyap,Katharina Glatz,Benjamin Kasenda,Karl Normington,James Broderick,Li Peng,Oliver M.T. Pearce
标识
DOI:10.1126/scitranslmed.abj1270
摘要
Immune checkpoint blockade (ICB) has substantially improved the prognosis of patients with cancer, but the majority experiences limited benefit, supporting the need for new therapeutic approaches. Up-regulation of sialic acid-containing glycans, termed hypersialylation, is a common feature of cancer-associated glycosylation, driving disease progression and immune escape through the engagement of Siglec receptors on tumor-infiltrating immune cells. Here, we show that tumor sialylation correlates with distinct immune states and reduced survival in human cancers. The targeted removal of Siglec ligands in the tumor microenvironment, using an antibody-sialidase conjugate, enhanced antitumor immunity and halted tumor progression in several murine models. Using single-cell RNA sequencing, we revealed that desialylation repolarized tumor-associated macrophages (TAMs). We also identified Siglec-E as the main receptor for hypersialylation on TAMs. Last, we found that genetic and therapeutic desialylation, as well as loss of Siglec-E, enhanced the efficacy of ICB. Thus, therapeutic desialylation represents an immunotherapeutic approach to reshape macrophage phenotypes and augment the adaptive antitumor immune response.
科研通智能强力驱动
Strongly Powered by AbleSci AI